# Progress Note 06 — Focused Visit (Care-plan review)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Diana, Princess of Wales (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML028-SYN-TD
- Date: 1990-07-13
- Fictional facility: St. Posthumous Health Center
- Fictional author: Imogen Castleford, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Care-plan review)

## Chief complaint

End-of-treatment review after 20 weeks of CBT-E. **S**

## History of present illness

Ms. Spencer returns at the end of CBT-E; she had her twentieth session last week and has a written relapse-prevention plan with her own early warning signs (skipping meals, a run of long days, and feeling low) and what to do about each. She has had no binge eating or vomiting for six weeks. She eats three meals and two snacks every day and no longer weighs herself daily. Her end-of-treatment EDE-Q global score is 1.6. She takes fluoxetine 60 mg each morning without side effects. Her mood is good, she sleeps well, and she has had no thoughts of suicide or self-harm. She has told two close friends about her treatment. **S**

| Element | Detail |
|---|---|
| Binge eating and vomiting | None for six weeks |
| CBT-E | Completed 20 sessions; written relapse-prevention plan |
| EDE-Q global score | 1.6 |
| Mood | Good; PHQ-9 4; item 9 scored 0 |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Energy good; weight steady |
| Gastrointestinal | Negative | No vomiting for six weeks |
| Ears, nose, mouth, and throat | Negative | No tooth sensitivity |
| Psychiatric | Negative | Mood good; no thoughts of suicide or self-harm |

4 systems reviewed. **S**

## Current medications

- Fluoxetine 60 mg oral tablet, one tablet by mouth each morning **S**

## Allergies

- No known allergy **S**

## Objective

BP 108/68 mmHg; pulse 66 bpm; respirations 14/min; temperature 36.5 °C; oxygen saturation 99% on room air; weight 62.1 kg; BMI 19.6 kg/m². All vital signs are synthetic.

Sodium: 140 mmol/L; Potassium: 4.2 mmol/L; Chloride: 103 mmol/L; Bicarbonate (total CO2): 25 mmol/L; Creatinine: 0.8 mg/dL; eGFR: 102 mL/min/1.73 m²; PHQ-9: 4. All results are synthetic.

## Change since baseline

- Sodium: 137 mmol/L at baseline, 140 mmol/L at this visit **S**
- Potassium: 3.1 mmol/L (low) at baseline, 4.2 mmol/L at this visit **S**
- Chloride: 94 mmol/L (low) at baseline, 103 mmol/L at this visit **S**
- Bicarbonate (total CO2): 32 mmol/L (high) at baseline, 25 mmol/L at this visit **S**
- Creatinine: 0.84 mg/dL at baseline, 0.8 mg/dL at this visit **S**
- eGFR: 97 mL/min/1.73 m² at baseline, 102 mL/min/1.73 m² at this visit **S**
- PHQ-9: 14 at baseline, 4 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; weight 62.1 kg, BMI 19.6; lying blood pressure 108/68 and pulse 66, standing 108/70 and pulse 72 after three minutes |
| Head and neck | Parotid glands normal in size; enamel erosion stable |
| Psychiatric | Bright and engaged; organized |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Bulimia nervosa, severe, now in early remission** (F50.23). No binge eating or vomiting for six weeks after 20 sessions of CBT-E with fluoxetine 60 mg; EDE-Q global score 1.6, from 3.9. Potassium 4.2 mmol/L. The coded problem stays active until remission is sustained. Relapse is most likely in the first year, so the relapse-prevention plan and fluoxetine continue. **S**
   - Continue fluoxetine 60 mg each morning for at least a year, then review a slow taper with Dr. Rosenthal.
   - Booster sessions with the therapist at one and three months.
   - Electrolytes only if vomiting returns.
   - Dental review as booked.
2. **Major depressive disorder, recurrent, moderate, in remission** (F33.1). PHQ-9 4, from 14: remission. Safety reviewed: no thoughts of suicide or self-harm; the safety plan and the 988 Suicide & Crisis Lifeline remain in her phone. **S**
   - Continue fluoxetine; PHQ-9 at each visit.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | Binge-eating and vomiting frequency (her self-monitoring record) | Every visit | Completed today | None for six weeks |
| Survey | Eating Disorder Examination Questionnaire (EDE-Q) global score | Baseline, mid-treatment, and end of treatment | Completed today | Global score 1.6 at the end of treatment, from 3.9 at intake |
| Examination | Weight and BMI | Every visit, and weekly in CBT-E sessions | Completed today | 62.1 kg, BMI 19.6, steady through treatment |
| Examination | Lying and standing pulse and blood pressure | Every visit while purging continues | Completed today | Lying 108/68, pulse 66; standing 108/70, pulse 72 (rise 6) |
| Laboratory | Potassium, chloride, bicarbonate, and creatinine | Weekly until potassium is normal twice, then at each medical visit while purging continues | Completed today | Potassium 4.2 mmol/L; sodium 140, chloride 103, bicarbonate 25 mmol/L; creatinine 0.80 mg/dL, eGFR 102. Repeat only if vomiting returns |
| Examination | Parotid and dental examination; dental protection | Every visit; a dental examination soon after diagnosis and regular dental reviews while vomiting continues | Up to date | Erosion stable; dental review in about three months |
| Medication safety | Fluoxetine dose, adherence, and side effects (nausea, sleep, agitation, sexual effects, suicidal thoughts) | At the start, one to two weeks after starting or a dose change, then every visit | Completed today | 60 mg; no side effects; continue for at least a year after remission |
| Self-management | CBT-E attendance and progress | Up to 20 sessions over 20 weeks, twice weekly for the first four weeks | Completed today | Completed 20 sessions; relapse-prevention plan written; booster sessions at one and three months |
| Self-management | Regular eating and dietitian review | Every visit | Completed today | Three meals and two snacks every day |
| Survey | Depression measure (PHQ-9) | Monthly during acute treatment, then periodically | Completed today | PHQ-9 4, item 9 scored 0: remission |
| Survey | Suicide-risk review, safety plan, lethal means, and the 988 Suicide & Crisis Lifeline | Every visit | Completed today | No thoughts of suicide or self-harm; safety plan and the 988 Suicide & Crisis Lifeline current |

## Goal progress

- No binge eating or vomiting for at least four weeks by the end of 20 weeks of CBT-E. Outcome by 1990-07-13: No binge eating or vomiting for six weeks. **S**
- Potassium at least 3.5 mmol/L on two checks within four weeks. Outcome by 1990-03-16: Potassium 3.6 and 3.9 mmol/L; supplement stopped. **S**
- Regular eating (three meals and two or three snacks) on most days by three months. Outcome by 1990-05-11: Regular eating on six or seven days a week. **S**
- PHQ-9 score below 5 by the end of treatment. Outcome by 1990-07-13: PHQ-9 4. **S**
- EDE-Q global score below 2.0 by the end of treatment. Outcome by 1990-07-13: EDE-Q global score 1.6. **S**

## Guideline basis

- The American Psychiatric Association Practice Guideline for the Treatment of Patients With Eating Disorders, Fourth Edition (2023), American Psychiatric Association (American Journal of Psychiatry 2023;180(2):167-171)
- Eating disorders: recognition and treatment (NICE guideline NG69) (2017, updated 2020), National Institute for Health and Care Excellence
- Depression and Suicide Risk in Adults: Screening (2023), U.S. Preventive Services Task Force
- VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024), United States Department of Veterans Affairs and Department of Defense
- CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026), Aether Forge

## Follow-up

- Booster CBT-E sessions at one and three months. Visit in three months, sooner for any return of bingeing or vomiting. Psychiatry review of fluoxetine after a year of remission. **S**

